A prospective cohort study was undertaken to assess the success of Ossur Unloader knee brace as non-operative management of isolated medial compartment osteoarthritis.

We recruited 12 volunteers (14 knees, mean age 63) with isolated medial compartment arthritis. They were clinically assessed, demographic data and Oxford knee scores were collected before the use of the braces. At 6 months, patient satisfaction, change in symptoms and repeat Oxford scores were noted.

Improvement was noted in 5 patients (6 knees, 42%) whose mean BMI was 29. They gained confidence, knee stability and pain relief. Their mean Oxford score had improved from 28 to 41.

Bracing was unsuccessful in 7 patients (8 knees, 58%) whose mean BMI was 33. These patients were disappointed and had discontinued its regular use. Their mean Oxford score only improved from 21 to 23.

As yet no patient has undergone a knee Arthroplasty. Comparative weight bearing radiographs with and without brace reveal no change in the weight bearing alignment. 42% of the patients with a mean baseline Oxford score of above 25 and a mean BMI of below 30 responded favourably. The main causes of failure were lack of improvement in symptoms, discomfort, skin irritation and poor patient compliance.

Study of failed Oxford medial unicompartmental knee replacements at the Royal Cornwall Hospital.

Over 200,000 osteoporotic fractures occur in the UK annually. Patients with fragility fractures are at highest risk of further fracture, though preventative treatment has been shown to reduce subsequent fracture incidence. In 2005, the National Institute for Health & Clinical Excellence (NICE) recommended bisphosphonates as a treatment option in women over 75 years without the need for prior DEXA scanning (Technology Appraisal Guidance 87). We prospectively reviewed the medication of such patients who were admitted to our Trauma Unit to identify if the NICE guidance was being followed.

Over a three month period between May and July 2007, 54 women over 75 years old were discharged from our Trauma Unit having sustained an osteoporotic fracture. We prospectively reviewed their medication to identify if a bisphosphonate had been commenced by the General Practitioner and their discharge letters to their General Practitioners to see if it had been suggested to start one. 7 of the 54 women (13%) were already on a bisphosphonate and were therefore excluded.

Only one (2%) of the discharge letters (written by the Orthopaedic doctor to the General Practitioner) recommended commencing a bisphosphonate. 6 of the 47 patients (13%) had been started on a bisphosphonate by the General Practitioner.

Nice guidance from 2005 is clearly not being implemented in our area. A minority of patients will have contraindications or allergies to bisphosphonates (up to 1 in 4 patients as highlighted recently by the National Osteoporosis Society). Important deficiencies in local services have been identified, particularly with respect to communication between secondary and primary care. This study lead to an education initiative to ensure the Trauma department and our local General Practitioners were aware of the NICE guidance. A second prospective audit is currently being undertaken to assess the effect on our service.

Introduction: Over 200,000 osteoporotic fractures occur in the UK annually. Patients with fragility fractures are at highest risk of further fracture, though preventative treatment has been shown to reduce subsequent fracture incidence. In 2005, the National Institute for Health & Clinical Excellence (NICE) recommended bisphosphonates as a treatment option in women over 75 years without the need for prior DEXA scanning (Technology Appraisal Guidance 87).

We prospectively reviewed the medication of such patients who were discharged from our Trauma Unit to identify if the NICE guidance was being followed.

Method: Over a three month period between May and July 2007, 54 women over 75 years old were discharged from our Trauma Unit having sustained an osteoporotic fracture.

We prospectively reviewed their medication to identify if a bisphosphonate had been commenced by the General Practitioner and their discharge letters to their General Practitioners to see if it had been suggested to start one.

Results: 7 of the 54 women (13%) were already on a bisphosphonate and were therefore excluded.

Only one (2%) of the discharge letters (written by the Orthopaedic doctor to the General Practitioner) recommended commencing a bisphosphonate.

6 of the 47 patients (13%) had been started on a bisphosphonate by the General Practitioner.

Conclusions: Nice guidance from 2005 is clearly not being implemented in our area. Some patients will have contraindications or allergies to bisphosphonates, however, they will be a minority (up to 1 in 4 patients as highlighted recently by the National Osteoporosis Society).

We believe the results demonstrate a lack of health promotion opportunities to prevent future fracture. Although there is clear focus and impetus for developing falls prevention services nationwide, this enthusiasm has not been translated across to bone health, despite the potential savings in terms of morbidity, mortality and healthcare costs.

Important deficiencies in local services have been identified, particularly with respect to communication between secondary and primary care.

This study lead to an education initiative to ensure the Trauma department and our local General Practitioners were aware of the NICE guidance. A second prospective audit is currently being undertaken to assess the effect on our service.